Literature DB >> 32034706

Introduction to Purinergic Signalling in the Brain.

Geoffrey Burnstock1.   

Abstract

ATP is a cotransmitter with glutamate, noradrenaline, GABA, acetylcholine and dopamine in the brain. There is a widespread presence of both adenosine (P1) and P2 nucleotide receptors in the brain on both neurons and glial cells. Adenosine receptors play a major role in presynaptic neuromodulation, while P2X ionotropic receptors are involved in fast synaptic transmission and synaptic plasticity. P2Y G protein-coupled receptors are largely involved in presynaptic activities, as well as mediating long-term (trophic) signalling in cell proliferation, differentiation and death during development and regeneration. Both P1 and P2 receptors participate in neuron-glial interactions. Purinergic signalling is involved in control of cerebral vascular tone and remodelling and has been implicated in learning and memory, locomotor and feeding behaviour and sleep. There is increasing interest in the involvement of purinergic signalling in the pathophysiology of the CNS, including trauma, ischaemia, epilepsy, neurodegenerative diseases, neuropsychiatric and mood disorders, and cancer, including gliomas.

Entities:  

Keywords:  ATP; Adenosine; Cotransmission; Glia; Gliomas; Memory; Neurodegenerative diseases; Neuromodulation; Neuron-gial interactions; Purinoceptors; Sleep; Trophic signalling

Mesh:

Substances:

Year:  2020        PMID: 32034706     DOI: 10.1007/978-3-030-30651-9_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  19 in total

1.  Purinergic Signaling in the Central Nervous System in Health and Disease.

Authors:  Peter Illes; Guang-Yin Xu; Yong Tang
Journal:  Neurosci Bull       Date:  2020-11-04       Impact factor: 5.203

Review 2.  Purinergic Modulation of Activity in the Developing Auditory Pathway.

Authors:  Sasa Jovanovic; Ivan Milenkovic
Journal:  Neurosci Bull       Date:  2020-10-11       Impact factor: 5.203

3.  Cerebrospinal fluid purinomics as a biomarker approach to predict outcome after severe traumatic brain injury.

Authors:  Nathan R Strogulski; Marco Antonio Stefani; Ana Elisa Böhmer; Gisele Hansel; Marcelo S Rodolphi; Afonso Kopczynski; Vitória G de Oliveira; Eduarda T Stefani; Juliana V Portela; André P Schmidt; Jean Pierre Oses; Douglas H Smith; Luis V Portela
Journal:  J Neurochem       Date:  2022-03-06       Impact factor: 5.546

4.  Characterization of the Expression of the ATP-Gated P2X7 Receptor Following Status Epilepticus and during Epilepsy Using a P2X7-EGFP Reporter Mouse.

Authors:  James Morgan; Mariana Alves; Giorgia Conte; Aida Menéndez-Méndez; Laura de Diego-Garcia; Gioacchino de Leo; Edward Beamer; Jonathon Smith; Annette Nicke; Tobias Engel
Journal:  Neurosci Bull       Date:  2020-09-07       Impact factor: 5.203

Review 5.  Purinergic signaling in tanycytes and its contribution to nutritional sensing.

Authors:  Magdiel Salgado; María Á García-Robles; Juan C Sáez
Journal:  Purinergic Signal       Date:  2021-05-21       Impact factor: 3.765

Review 6.  In Search of a Role for Extracellular Purine Enzymes in Bone Function.

Authors:  Mariachiara Zuccarini; Patricia Giuliani; Francesco Caciagli; Renata Ciccarelli; Patrizia Di Iorio
Journal:  Biomolecules       Date:  2021-04-30

Review 7.  Glial Purinergic Signaling in Neurodegeneration.

Authors:  Marie J Pietrowski; Amr Ahmed Gabr; Stanislav Kozlov; David Blum; Annett Halle; Kevin Carvalho
Journal:  Front Neurol       Date:  2021-05-14       Impact factor: 4.003

8.  Editorial: P2X7 as Common Therapeutic Target in Brain Diseases.

Authors:  Tobias Engel; Annette Nicke; Jan M Deussing; Beata Sperlagh; Miguel Diaz-Hernandez
Journal:  Front Mol Neurosci       Date:  2021-04-27       Impact factor: 5.639

Review 9.  The Role of Purinergic Receptors in the Circadian System.

Authors:  Amira A H Ali; Gayaneh Avanes Avakian; Charlotte von Gall
Journal:  Int J Mol Sci       Date:  2020-05-12       Impact factor: 5.923

Review 10.  Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome.

Authors:  Júlia Leão Batista Simões; Margarete Dulce Bagatini
Journal:  J Neuroimmune Pharmacol       Date:  2021-01-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.